Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.14 USD

806.14
3,896,330

-12.79 (-1.56%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $805.57 -0.57 (-0.07%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Corcept Initiates Phase III Study for Cushing's Syndrome

by Zacks Equity Research

Corcept (CORT) doses first patient in the phase III study of relacorilant for the treatment of Cushing's syndrome.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $115.81 in the latest trading session, marking a +1.74% move from the prior day.

Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings

by Zacks Equity Research

FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.

Seattle Genetics' Adcetris Gets Breakthrough Therapy Status

by Zacks Equity Research

Seattle Genetics' (SGEN) Adcetris gets Breakthrough Therapy designation by the FDA for the frontline treatment of certain lymphoma subtypes.

Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug

by Zacks Equity Research

The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee vote for Mallinckrodt (MNK) abuse-deterrent drug.

Lilly Offers Updates on Progress of Headache Disorder Drugs

by Zacks Equity Research

Eli Lilly (LLY) files NDA with FDA for migraine candidate, lasmiditan. FDA grants Breakthrough Therapy status to Emgality for episodic cluster headache indication.

Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx

by Zacks Equity Research

Exelixis (EXEL) and partner Ipsen receive EU approval for the label expansion of Cabometyx (cabozantinib) tablets as a monotherapy for HCC in adults.

AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study

by Zacks Equity Research

AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.

Merck Starts Rolling BLA Submission for Ebola Vaccine V920

by Zacks Equity Research

Merck (MRK) begins the rolling submission of a BLA for its investigational Ebola vaccine candidate V920 to the FDA.

Shire's Filing Accepted by FDA for Gattex's Label Expansion

by Zacks Equity Research

The FDA accepts Shire's (SHPG) sNDA and is expected to take action in March 2019.

Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates

by Zacks Equity Research

Bayer (BAYRY) surpasses earnings and sales estimates in the third quarter of 2018 and reiterates outlook for 2018.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $113.20 in the latest trading session, marking a +0.88% move from the prior day.

AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark

by Zacks Equity Research

AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.

Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update

by Zacks Equity Research

Catalyst (CPRX) provides pipeline update and the FDA sets action date of Nov 28, 2018 for its lead pipeline candidate, Firdapse during the third quarter of 2018.

Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag

by Zacks Equity Research

Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.

Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Celldex (CLDX) reports narrower-than-expected loss in Q3. Revenues fall on reduced contract revenues and also miss estimates.

Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug

by Zacks Equity Research

Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.

Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise

by Zacks Equity Research

Shares of Horizon Pharma (HZNP) rise almost 16%, owing to record quarterly sales during the third quarter of 2018.

Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up

by Zacks Equity Research

Nektar's (NKTR) earnings and sales beat estimates in the third quarter. The company enters oncology clinical collaboration with Pfizer to evaluate NKTR-214 combination therapy.

AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales

by Zacks Equity Research

AstraZeneca (AZN) beats earnings and sales estimates in the third quarter and maintains previously issued outlook for 2018. AstraZeneca's newer medicines sales rise 86% in the quarter.

Mallinckrodt (MNK) Beats on Q3 Earnings Estimates, Ups View

by Zacks Equity Research

Mallinckrodt (MNK) surpasses both earnings and sales estimates in the third quarter of 2018.

Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review

by Zacks Equity Research

Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.

Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes

by Zacks Equity Research

Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.

Ryan McQueeney headshot

Will Stocks Gain After the Elections? & Earnings from CVS, LLY, HEAR

by Ryan McQueeney

Ryan McQueeney chats with Dave Bartosiak about the near-term outlook for stocks after the midterm elections and the earnings outlook for Turtle Beach ahead of its report. The host also recaps earnings results from CVS, Eli Lilly, and Regeneron.

September JOLTS Report In Spotlight

by Zacks Equity Research

September JOLTS Report In Spotlight